{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T17:04:20Z","timestamp":1781197460535,"version":"3.54.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cmi.2026.03.039","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:01:40Z","timestamp":1775545300000},"page":"1045-1046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A cutting-edge vaccine could address a gap in protection against Ebola virus disease"],"prefix":"10.1016","volume":"32","author":[{"given":"Armand","family":"Sprecher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Jonckheere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Van Herp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.03.039_bib1","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S1473-3099(24)00419-5","article-title":"Effectiveness of rVSV-ZEBOV vaccination during the 2018-20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study","volume":"24","author":"Meakin","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.03.039_bib2","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa1904387","article-title":"Ebola outbreak response in the DRC with rVSV-ZEBOV-GP ring vaccination","volume":"391","author":"Muyembe","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.03.039_bib3","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S1473-3099(23)00819-8","article-title":"Case fatality risk among individuals vaccinated with rVSV\u0394G-ZEBOV-GP: a retrospective cohort analysis of patients with confirmed Ebola virus disease in the Democratic Republic of the Congo","volume":"24","author":"Coulborn","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.03.039_bib4","unstructured":"Merck Sharp & Dohme LLC. ERVEBO (Ebola Zaire Vaccine, Live) [package insert]. Food Drug Adm. Published 2019. Accessed February 8, 2026. https:\/\/www.fda.gov\/media\/133748\/download."},{"key":"10.1016\/j.cmi.2026.03.039_bib5","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.03.039_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112402","article-title":"Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates","volume":"42","author":"Gunn","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.cmi.2026.03.039_bib7","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/v17030342","article-title":"Durability of immunogenicity and protection of rVSV\u0394G-ZEBOV-GP vaccine in a nonhuman primate EBOV challenge model","volume":"17","author":"Bixler","year":"2025","journal-title":"Viruses"},{"issue":"Suppl 7","key":"10.1016\/j.cmi.2026.03.039_bib8","doi-asserted-by":"crossref","first-page":"S671","DOI":"10.1093\/infdis\/jiad208","article-title":"Preexisting immunity does not prevent efficacy of vesicular stomatitis virus-based filovirus vaccines in nonhuman primates","volume":"228","author":"Marzi","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2026.03.039_bib9","doi-asserted-by":"crossref","unstructured":"Huttner A, de La Vega M-A, Boehm-Bosmani C, Boyer J, Eberhardt C, Fontannaz P, et al. A Phase Ib, Placebo-controlled randomized clinical trial of the Ebolavirus DNA vaccine candidate INO-4201 followed by electroporation as booster vaccination in healthy, rVSV\u0394G-ZEBOV-GP-primed Volunteers (Boost-EBOV). Clin Microbiol Infect. 2026;32:1158\u201364. https:\/\/doi.org\/10.1016\/j.cmi.2026.01.019.","DOI":"10.1016\/j.cmi.2026.01.019"},{"key":"10.1016\/j.cmi.2026.03.039_bib10","article-title":"New Ebola outbreak likely sparked by a person infected 5 years ago","author":"Kupferschmidt","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.cmi.2026.03.039_bib11","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejpb.2023.08.005","article-title":"Physical characteristics and stability profile of recombinant plasmid DNA within a film matrix","volume":"190","author":"Kieu Doan","year":"2023","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.cmi.2026.03.039_bib12","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3390\/vaccines8040741","article-title":"Intramuscular and intradermal electroporation of HIV-1 PENNVAX-GP\u00ae DNA vaccine and IL-12 is safe, tolerable, acceptable in healthy adults","volume":"8","author":"Edupuganti","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.cmi.2026.03.039_bib13","article-title":"Landmark vaccine deals signal Africa\u2019s shift toward local manufacturing","volume":"14","author":"Adepoju","year":"2025","journal-title":"Health Policy Watch February"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26001771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26001771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:24:03Z","timestamp":1781195043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26001771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1198743X26001771"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.03.039","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A cutting-edge vaccine could address a gap in protection against Ebola virus disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.03.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}